1. Home
  2. DXC vs RAPP Comparison

DXC vs RAPP Comparison

Compare DXC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$15.28

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

BUY

Current Price

$25.28

Market Cap

1.5B

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
DXC
RAPP
Founded
1959
2022
Country
United States
United States
Employees
115000
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2016
2024

Fundamental Metrics

Financial Performance
Metric
DXC
RAPP
Price
$15.28
$25.28
Analyst Decision
Hold
Strong Buy
Analyst Count
8
16
Target Price
$11.21
★ $62.71
AVG Volume (30 Days)
★ 4.3M
608.6K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.34
EPS
★ 0.73
N/A
Revenue
★ $12,644,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.94
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.90
$23.75
52 Week High
$15.68
$52.93

Technical Indicators

Market Signals
Indicator
DXC
RAPP
Relative Strength Index (RSI) 80.81 25.91
Support Level $11.26 N/A
Resistance Level $15.54 $31.57
Average True Range (ATR) 0.66 2.11
MACD 0.32 0.04
Stochastic Oscillator 99.89 5.69

Price Performance

Historical Comparison
DXC
RAPP

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: